What Can Go Wrong With Peptides: A Risk Assessment

The Single Biggest Risk Isn't the Peptide

For most people, the biggest health risk with research peptides has little to do with how the molecule works. It's the source.

These products don't come from a pharmacy with a prescription. They're sold online as "research chemicals," so the vial could be underdosed, overdosed, contaminated with bacterial residue, or a different substance entirely. A preprint posted in April 2026 (not yet peer-reviewed) analyzed 6,441 gray-market samples of 14 peptides from a public independent-testing dataset. Depending on which quality standard the authors applied, 41.6% to 71.1% failed basic criteria for purity and amount, and 156 reports showed vials that didn't contain the stated peptide. Of the 243 samples with endotoxin results, 15% had measurable endotoxin, a bacterial toxin left over from manufacturing. An injection-site reaction could be a simple histamine response, or it could be a low-grade infection from a non-sterile process.

FDA makes a related point in its list of compounding substances with safety concerns: for almost every research peptide it reviewed, it flags a risk of immune reactions from aggregation and peptide-related impurities. Some side effects people blame on a peptide may come from whatever else is in the vial, and symptoms alone can't tell the two apart. Where a supplier is based also changes what oversight applies, if any; our page on how peptide rules differ by country covers that.

Athletes carry an extra risk. WADA's 2026 Prohibited List bans BPC-157 (S0), growth hormone secretagogues such as ipamorelin and CJC-1295 (S2.2.4), and IGF-1 analogues and TB-500 (S2.3) at all times. Our overview of peptide rules in sport explains how those categories work.

The Common, Low-Impact Annoyances

Even with a cleaner product, users describe some common, generally low-grade side effects, mostly in the first couple of weeks.

• Injection Site Reactions: Redness, itching, or a small welt at the injection site come up often in user reports, especially with BPC-157 and GHK-Cu (GHK-Cu users often describe burning or stinging that lasts hours). Many users put this down to a local histamine reaction, and most say it settles within a week or two. Rotating sites and sterile technique are the standard advice in community guides. A site that turns hot, swollen, or more painful over time points to infection rather than irritation, and that needs medical attention.

• Water Retention & Numbness: Growth hormone secretagogues (such as ipamorelin, tesamorelin, or CJC-1295) signal the pituitary to release more growth hormone (GH), which raises IGF-1. Higher GH and IGF-1 can make the body hold more sodium and water, which shows up as puffy hands and feet or a small jump on the scale. Some users describe carpal-tunnel-like symptoms at higher doses: numbness or tingling in the hands and wrists. Users commonly treat these symptoms as a sign to lower the dose. In the short term they're usually described as uncomfortable rather than dangerous.

• Headaches, Flushing & Nausea: GHRPs, CJC-1295 and melanotan II can cause a head rush, flushing, headache, or nausea shortly after injection. For CJC-1295, FDA's compounding review lists increased heart rate and a "systemic vasodilatory reaction" among serious adverse events. With melanotan II, nausea can be severe and is a common reason users stop.

The Real-Deal Risks: What to Actually Monitor

These risks depend on the class of peptide, and they're the ones people typically track with bloodwork.

GH Secretagogues and Insulin Resistance

This is the main concern for anyone using GHRH analogues and GHRPs for performance or longevity. Raising GH and IGF-1 for long periods can lower insulin sensitivity, so the pancreas has to work harder to control blood sugar. Over time, that can drift toward prediabetes.

The best human data come from a related compound. In a 2-year randomized trial of 65 healthy adults aged 60-81, the oral GH secretagogue MK-677 (25 mg daily) raised fasting glucose by about 5 mg/dL on average and lowered insulin sensitivity. FDA's compounding review notes higher blood glucose from reduced insulin sensitivity with GHRP-6, and reports of increased insulin requirements with GHRP-2. For ipamorelin, FDA cites serious adverse events, including deaths, in a study that gave it intravenously after surgery; causality wasn't established. Lifters also point out that worse insulin sensitivity can work against the body-composition goals that led them to these compounds.

What people monitor: Users, and the clinicians who see them, commonly describe baseline bloodwork and a repeat test 6-8 weeks in.

• Fasting Glucose: Under 100 mg/dL is the usual normal cutoff. A steady rise from a person's own baseline is the signal people watch for.
• HbA1c: This reflects average blood sugar over about 3 months, and it's the marker most people focus on. Below 5.7% is the normal range; 5.7-6.4% is the prediabetes range. A move from, say, 5.2% to 5.6% is still normal, but it's the kind of trend users report treating as a reason to stop or take a break.

IGF-1 Variants and Cell Proliferation

IGF-1 LR3 is an engineered IGF-1 analogue that users take hoping for hyperplasia (new muscle cell formation) and hypertrophy. As of October 2026, no human study of LR3 has been published; the evidence is preclinical, mostly in rats (see our IGF-1 LR3 profile). IGF-1 is a systemic growth factor, so it doesn't act only on muscle, and rat studies have recorded growth of the gut and other organs.

The fear that IGF-1 will start a cancer gets more attention than the more plausible concern: that a growth factor could speed up cancer cells that are already there and undiagnosed, such as a small prostate tumor. The mechanism makes biological sense, but nobody has measured it for LR3 in people. That's why personal and family cancer history weighs so heavily in any risk discussion about systemic growth factors. The more immediate risk users report is hypoglycemia (shakiness, sweating), and many eat carbohydrates around injections to avoid it.

Melanotan II's Unique Profile

MT-II acts on several melanocortin receptors, so its risks differ from the other peptides here. Most of the serious events come from case reports, which show what can happen but not how often. Our melanotan II profile covers the trial data in more detail.

• Cardiovascular and Neurological: FDA cites published case reports of sympathomimetic toxidrome (a pattern of racing heart, high blood pressure and agitation) and posterior reversible encephalopathy syndrome (PRES), a brain-swelling syndrome usually tied to sharp rises in blood pressure.
• Moles & Skin Pigmentation: MT-II stimulates melanin production. Case reports and user reports describe new moles and darkening of existing ones. Several case reports describe melanoma in users, including a 20-year-old woman in Denmark diagnosed three months after a 3-4 week course of self-injections combined with sunbed use (published 2014). Causality hasn't been established, but any rapid change in a mole's size, shape, or color is the standard reason to see a dermatologist.
• Priapism: Spontaneous erections were common in the early trials. FDA lists priapism (an erection lasting hours) among the serious events in case reports, and it's a medical emergency.

Long-Term Questions We Can't Answer Yet

Nobody knows what a decade of BPC-157 use, or five straight years of ipamorelin, does to a person. Those studies don't exist.

The short-term animal safety data for BPC-157 look clean. A 2025 systematic review found no acute toxicity across several organs in rats and dogs and no lethal dose across a wide range of doses, but those studies ran for under 6 weeks, and the review found no clinical safety data in humans. The three small human pilots published so far reported no adverse events, but together they involved about 30 people. For TB-500 the gap is wider: as of October 2026, FDA says it has found no human exposure data for the fragment sold under that name. Rats live for about two years. We live for eighty. Claims that these compounds are safe for long-term use go beyond the data.

The length of exposure changes the question. An 8-week course of BPC-157 for a nagging tendon problem carries a different, and smaller, unknown than a year-round low-dose protocol for general well-being.

Risks by Peptide Class

Compared with oral anabolic steroids, which have well-documented liver, lipid, and hormone-axis (HPTA) effects, the risks of these peptides are less well mapped. A few are documented in human trials, such as GH-related glucose changes. Many haven't been studied at all, and for coaches and support staff weighing what to tell athletes, our guide to advising athletes without prescribing picks up from here.